Issue 4/2025
Gledzharska1, R., Konakchieva1, M., Milchev2, A.
1 Clinic of Gastroenterology, MHAT MMA – Sofia
2 Clinic of Second Abdominal Surgery, MHAT MMA – Sofia
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), like liraglutide, semaglutide and exenatid are used in type 2 diabetes and obesity because there are effective in lowering glycamic index, reducing body weight loss and arterial hypertonia and inducing sleep apnea. Most common adverse events (GI AEs) are gastrointestinal like nausea, vomiting, diarrhoea and/or constipation. In clinical practice, it is necessary strict monitoring of patients to be carried out, in order to minimize the severity and duration of GI AEs during undergoing treatment. There are specific guidelines for recomendation how to reach the maintenance dose and how to proceed if GI AEs develop during dose-escalation. Secondly, specific directions are set about how to avoid/minimize nausea, vomiting, diarrhoea and constipation symptoms.
Key words: Type 2 diabetes; obesity; glucagon-like peptide-1 receptor agonists; gastrointestinal adverse events;
Address for correspondence:
Dr. R. Gledzharska
VVMA
3, „St. Georgi Sofiyski“, Str.
1606, Sofia